Get the Stockscreener App
41.25
1.30%
0.53
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Teva Pharmaceutical Industries Ltd Adr stock is traded at $41.25, with a volume of 4.53M.
It is up +1.30% in the last 24 hours and up +5.10% over the past month.
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
See More
Previous Close:
$40.72
Open:
$41.3
24h Volume:
4.53M
Relative Volume:
0.65
Market Cap:
$48.11B
Revenue:
$17.53B
Net Income/Loss:
$1.58B
P/E Ratio:
30.65
EPS:
1.3457
Net Cash Flow:
$444.18M
1W Performance:
+5.10%
1M Performance:
+5.10%
6M Performance:
+30.50%
1Y Performance:
+108.54%
1-Day Range:
$41.15
$41.85
1-Week Range:
$40.12
$42.02
52-Week Range:
$18.82
$42.02
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
Name
Teva Pharmaceutical Industries Ltd Adr
Sector
Phone
972 (3) 914-8213
Address
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Compare TEVA vs TAK, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.25 | 48.11B | 17.53B | 1.58B | 444.18M | 1.3457 |
TAK
Takeda Pharmaceutical Co Adr
|
19.63 | 62.71B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.965 | 43.82B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
78.69 | 32.51B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
548.81 | 23.54B | 3.17B | 1.29B | 1.01B | 27.09 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-26 | Initiated | TD Cowen | Buy |
| Sep-23-26 | Initiated | Oppenheimer | Outperform |
| Sep-09-26 | Initiated | Leerink Partners | Outperform |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Dec-05-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-06-25 | Initiated | Goldman | Buy |
| May-28-25 | Initiated | Truist | Buy |
| May-12-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-10-24 | Upgrade | Argus | Hold → Buy |
| Mar-08-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Feb-12-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-23-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Upgrade | Piper Sandler | Underweight → Neutral |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Nov-27-23 | Upgrade | UBS | Neutral → Buy |
| Jul-06-23 | Upgrade | UBS | Sell → Neutral |
| May-25-23 | Initiated | Morgan Stanley | Equal-Weight |
| May-18-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-19-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-14-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-04-22 | Downgrade | UBS | Neutral → Sell |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Aug-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-14-22 | Resumed | UBS | Neutral |
| May-17-22 | Upgrade | BofA Securities | Underperform → Neutral |
| May-04-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Apr-05-22 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-25-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-27-22 | Downgrade | Argus | Buy → Hold |
| Oct-28-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-04-21 | Downgrade | UBS | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-25-20 | Initiated | Oppenheimer | Perform |
| Aug-06-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-27-20 | Resumed | Goldman | Neutral |
| Jun-01-20 | Upgrade | SunTrust | Hold → Buy |
| Apr-24-20 | Resumed | Citigroup | Neutral |
| Apr-06-20 | Upgrade | UBS | Neutral → Buy |
| Feb-24-20 | Downgrade | Edward Jones | Hold → Sell |
| Nov-12-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-17-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Aug-07-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-19-19 | Initiated | Wolfe Research | Peer Perform |
| Jul-15-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-19 | Resumed | Credit Suisse | Neutral |
| Jul-05-19 | Upgrade | Argus | Hold → Buy |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Jun-03-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| May-28-19 | Downgrade | UBS | Buy → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Mar-07-19 | Resumed | UBS | Buy |
View All
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Latest News
Corcept Looks To End Teva's Mifepristone Antitrust Case - Law360
Small Molecule Active Pharmaceutical Ingredient Market Insights: Demand Trends, Competitive Landscape & Industry Outlook - EIN News
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down - Zacks Investment Research
ETFs Investing in Teva Pharmaceutical Industries Limited Stocks - TradingView
Teva Pharmaceutical Industries Ltd. to Host R&D Day on November 11, 2026 - Quiver Quantitative
Teva to Host R&D Day on Wednesday, November 11 in New York City - GlobeNewswire Inc.
Teva to Host R&D Day on Wednesday, November 11 in New York City - GlobeNewswire
Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Target Raised at JPMorgan Chase & Co. - MarketBeat
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia - Zacks Investment Research
Teva Wins FDA Approval For Schizophrenia Innovation - Healthcare Digital
Teva Pharmaceutical Industries (TEVA): Transitioning from Generics to High-Margin Branded Drugs - Yahoo Finance
ETFs Investing in Teva Pharmaceutical Industries Limited Stocks - TradingView
Pretax income of Teva Pharmaceutical Industries Limited – BMV:TEVA1/N - TradingView
Teva Pharmaceutical Industries (TEVA) Stock Forecasts - Yahoo Finance
Teva Pharmaceutical Industries Ltd (HAM:TEVA) Stock Earnings Transcripts - GuruFocus
Teva Pharmaceutical Industries Ltd (HAM:TEVA) Stock Price, Trades & News - GuruFocus
Teva Pharmaceutical Industries Ltd. Advanced Charts | TEVA - Barron's
Teva Pharmaceutical Industries Ltd. Financials | TEVA - Barron's
Israeli Pharma Giant Teva Wins FDA Approval for Monthly Schizophrenia Injection Weltruza - Haaretz
Teva Pharmaceutical Industries (TEVA) Stock Forecasts - Yahoo! Finance Canada
Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth InitiativesSlideshow (NYSE:TEVA) 2026-10-09 - Seeking Alpha
Teva wins FDA approval for monthly schizophrenia injection Weltruza - Reuters
Oppenheimer Adjusts Teva Pharmaceutical Industries PT to $52 From $50, Maintains Outperform Rating - Yahoo Finance
Teva debuts Weltruza in schizophrenia as much-hyped FDA nod for long-acting olanzapine arrives - Fierce Pharma
J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold? - Zacks Investment Research
Teva Pharmaceutical Industries Ltd. Research & Ratings | TEVA1N - Barron's
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia - Teva Pharmaceuticals
Teva Pharmaceutical Industries Ltd. Company & People | TEVA - Barron's
Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price - Simply Wall Street
Teva Pharmaceutical Industries (NYSE:TEVA) Stock Forecast & Analyst Predictions - Simply Wall Street
Here's Why You Should Add URGN Stock to Your Portfolio Now - Zacks Investment Research
Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround - The Motley Fool
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Short Interest Update - MarketBeat
Is Teva Pharmaceutical Industries (TEVA) Undervalued Following New Phase 3 Schizophrenia Data? - simplywall.st
Teva, Wyeth Show How Claimed Advances Shape Enablement - Law360
Teva Pharmaceutical Industries Ltd. to Report Third Quarter 2026 Financial Results on November 3, 2026 - quiverquant.com
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET - GlobeNewswire
Teva Releases Q3 2026 Aide Memoire - GlobeNewswire
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET - GlobeNewswire Inc.
Teva Releases Q3 2026 Aide Memoire - GlobeNewswire Inc.
Viatris, Teva initiated at Outperform at Oppenheimer - Seeking Alpha
Teva Pharmaceutical Industries(TEVA.US) Director Sells US$14.36 Million in Common Stock - Moomoo
Teva Pharmaceutical Industries (TEVA) Stock Forecasts - finance.yahoo.com
Oppenheimer Initiates Coverage on Teva Pharmaceutical Industries (NYSE:TEVA) - MarketBeat
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings - MarketBeat
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings - Yahoo Finance
TEVA: Investment grade status enables accelerated innovation, robust launches, and renewed generics growth - TradingView
TEVA: Focus shifts to innovation, high-margin launches, and renewed growth in generics and biosimilars - TradingView
Brian Savage Sells 7,342 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock - MarketBeat
Teva Pharmaceutical Industries (NYSE:TEVA) Director Roberto Mignone Sells 367,600 Shares - MarketBeat
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MIGNONE ROBERTO | Director |
Sep 18 '26 |
Sale |
39.06 |
367,600 |
14,356,802 |
0 |
| Bridger Management, LLC (1) | Shareholder |
Sep 18 '26 |
Proposed Sale |
39.19 |
367,600 |
14,406,244 |
0 |
| Savage Brian | Officer |
Sep 18 '26 |
Proposed Sale |
38.85 |
7,028 |
273,062 |
0 |
| Savage Brian | Interim Chief Legal Officer |
Sep 18 '26 |
Sale |
38.85 |
7,342 |
285,215 |
8,500 |
| Satchi-Fainaro Ronit | Director |
Aug 21 '26 |
Sale |
37.25 |
415 |
15,459 |
111,986 |
| Weiss Amir | Chief Accounting Officer |
Aug 21 '26 |
Option Exercise |
19.61 |
2,500 |
49,025 |
15,571 |
| Weiss Amir | Chief Accounting Officer |
Aug 21 '26 |
Sale |
37.62 |
9,445 |
355,301 |
13,071 |
| Lippman Evan | EVP, Business Development |
Aug 17 '26 |
Sale |
36.57 |
18,600 |
680,291 |
25,591 |
| Lippman Evan | Officer |
Aug 17 '26 |
Proposed Sale |
36.57 |
18,600 |
680,291 |
0 |
| Zaks Tal Zvi | Director |
Aug 05 '26 |
Sale |
34.87 |
17 |
593 |
73,247 |
2.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):